{"paper_id":"e22f6497-ed70-48b3-adde-5879593b4b0c","body_text":"Abstract\nBackground\nHeavy menstrual bleeding (HMB) is an important health problem affecting up to 30 % of reproductive age women, interfering with their quality of life. Medical therapy, with the avoidance of unnecessary surgery, is an attractive option.\nPurpose\nTo provide a comprehensive review of the current medical treatments available for idiopathic HMB and to focus on the newly introduced modalities. Furthermore, to provide a practical algorithm based on the best available evidence.\nMethods\nA PubMed search was conducted looking for the different trials, reviews and various guidelines relating to medical treatment of idiopathic HMB.\nResults\nThe most effective medical treatment for idiopathic HMB is the levonorgestrel-releasing intrauterine system. It provides a reliable long-term effect. Importantly, there is a growing scientific evidence for new modalities entailing; modified-release formulation of tranexamic acid, the new four-phasic estradiol valerate/dienogest contraceptive pills and combined contraceptive vaginal ring. Also, vaginal danazol has been tried.\nConclusion\nMaintenance of status quo, i.e., keeping first-line treatment of idiopathic HMB as medical treatment is an essential issue. Modified-release formulation of tranexamic acid, the new four-phasic contraceptive pills and contraceptive vaginal ring are recently added to the medical armamentarium for treatment of idiopathic HMB increasing its efficacy.\nSimilar content being viewed by others\nReferences\nHallberg L, Högdahl AM, Nilsson L, Rybo G (1966) Menstrual blood loss-a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 45:320–351. doi:10.3109/00016346609158455\nFraser IS, Critchley HO, Broder M, Munro MG (2011) The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med 29:383–390. doi:10.1055/s-0031-1287662\nMunro MG, Critchley HO, Fraser IS (2012) The FIGO systems for nomenclature and classification of causes of abnormal uterine bleeding in the reproductive years: who needs them? Am J Obstet Gynecol. doi:10.1016/j.ajog.2012.01.046\nFraser IS, Critchley HO, Munro MG, Broder M (2007) Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? Hum Reprod 22:635–643. doi:10.1093/humrep/del478\nWarner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD (2004) Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia? Am J Obstet Gynecol 190:1224–1229. doi:10.1016/j.ajog.2003.11.016\nShapley M, Jordan K, Croft PR (2004) An epidemiological survey of symptoms of menstrual loss in the community. Br J Gen Pract 54:359–363\nHarlow SD, Campbell OM (2004) Epidemiology of menstrual disorders in developing countries: a systematic review. BJOG 111:6–16. doi:10.1046/j.1471-0528.2003.00012.x\nSantos IS, Minten GC, Valle NC et al (2011) Menstrual bleeding patterns: a community-based cross-sectional study among women aged 18–45 years in Southern Brazil. BMC Womens Health 11:26. doi:10.1186/1472-6874-11-26\nMatteson KA, Boardman LA, Munro MG, Clark MA (2009) Abnormal uterine bleeding: a review of patient-based outcome measures. Fertil Steril 92:205–216. doi:10.1016/j.fertnstert.2008.04.023\nShapley M, Jordan K, Croft PR (2002) Why women consult with increased vaginal bleeding: a case control study. Br J Gen Pract 52:108–113\nShankar M, Chi C, Kadir RA (2008) Review of quality of life: menorrhagia in women with or without inherited bleeding disorders. Haemophilia 14:15–20. doi:10.1111/j.1365-2516.2007.01586.x\nNational Collaborating Centre for Women’s and Children’s Health/National Institute for Health and Clinical Excellence (2007) Heavy menstrual bleeding. NICE clinical guideline 44, RCOG Press, London, UK. Available at: http://www.nice.org.uk/nicemedia/pdf/CG44FullGuideline.pdf\nDuckitt K, Collins S (2012) Menorrhagia. Clin Evid (Online). 18 Jan 2012. pii: 0805\nCritchley HO, Maybin JA (2011) Molecular and cellular causes of abnormal uterine bleeding of endometrial origin. Semin Reprod Med 29:400–409. doi:10.1055/s-0031-1287664\nNelson AL, Teal SB (2007) Medical therapies for chronic menorrhagia. Obstet Gynecol Surv 62:272–281. doi:10.1097/01.ogx.0000259228.70277.6f\nDrife JO (2011) Oral contraceptives and heavy periods (editorial). Obstet Gynecol 117:773–774. doi:10.1097/AOG.0b013e318212b333\nClarke J (2010) Treatment of heavy menstrual bleeding (editorial). BMJ 341:c3771. doi:10.1136/bmj.c3771\nLukes AS, Kouides PA, Moore KA (2011) Tranexamic acid: a novel oral formulation for the treatment of heavy menstrual bleeding. Womens Health (Lond Engl) 7:151–158. doi:10.2217/whe.11.9\nJensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS (2011) Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol 117:777–787. doi:10.1097/AOG.0b013e3182118ac3\nAlexander NJ, Baker E, Kaptein M, Karck U, Miller L, Zampaglione E (2004) Why consider vaginal drug administration? Fertil Steril 82:1–12. doi:10.1016/j.fertnstert.2004.01.025\nAbu Hashim H, Alsherbini W, Bazeed M (2012) Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception 85:246–252. doi:10.1016/j.contraception.2011.07.012\nLuisi S, Razzi S, Lazzeri L, Bocchi C, Severi FM, Petraglia F (2009) Efficacy of vaginal danazol treatment in women with menorrhagia during fertile age. Fertil Steril 92:1351–1354. doi:10.1016/j.fertnstert.2008.08.017\nJabbour HN, Sales KJ, Smith OP, Battersby S, Boddy SC (2006) Prostaglandin receptors are mediators of vascular function in endometrial pathologies. Mol Cell Endocrinol 252:191–200. doi:10.1016/j.mce.2006.03.025\nEndrikat J, Vilos G, Muysers C, Fortier M, Solomayer E, Lukkari-Lax E (2012) The levonorgestrel-releasing intrauterine system provides a reliable, long-term treatment option for women with idiopathic menorrhagia. Arch Gynecol Obstet 285:117–121. doi:10.1007/s00404-011-1902-1\nKaunitz AM, Inki P (2012) The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review. Drugs 72:193–215. doi:10.2165/11598960-000000000-00000\nKaunitz AM, Meredith S, Inki P, Kubba A, Sanchez-Ramos L (2009) Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol 113:1104–1116. doi:10.1097/AOG.0b013e3181a1d3ce\nBahamondes MV, de Lima Y, Teich V, Bahamondes L, Monteiro I (2012) Resources and procedures in the treatment of heavy menstrual bleeding with the levonorgestrel-releasing intrauterine system (LNG-IUS) or hysterectomy in Brazil. Contraception. doi:10.1016/j.contraception.2011.12.005\nMatteson KA, Anderson BL, Pinto SB, Lopes V, Schulkin J, Clark MA (2011) Practice patterns and attitudes about treating abnormal uterine bleeding: a national survey of obstetricians and gynecologists. Am J Obstet Gynecol 205:321.e1–8. doi:10.1016/j.ajog.2011.05.016\nFarquhar C, Brown J (2009) Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database Syst Rev (4):CD000154. doi:10.1002/14651858.CD000154\nFraser IS, McCarron G (1991) Randomized trial of 2 hormonal and 2 prostaglandin- inhibiting agents in women with a complaint of menorrhagia. Aust N Z J of Obstet Gynaecol 31:66–70. doi:10.1111/j.1479-828X.1991.tb02769.x\nEndrikat J, Shapiro H, Lukkari-Lax E, Kunz M, Schmidt W, Fortier M (2009) A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can 31:340–347\nShabaan MM, Zakherah MS, El-Nashar SA, Sayed GH (2011) Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception 83:48–54. doi:10.1016/j.contraception.2010.06.011\nMiller L, Notter KM (2001) Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol 98:771–778\nCollaborative Study Group on the Desogestrel containing Progestogen-only Pill (1998) A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Eur J Contracept Reprod Health Care 3:169–178\nLethaby A, Irvine G, Cameron I (2008) Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev (1):CD001016. doi:10.1002/14651858.CD001016.pub2\nFraser IS (1990) Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynaecol 30:353–356. doi:10.1111/j.1479-828X.1990.tb02028.x\nKriplani A, Kulshrestha V, Agarwal N, Diwakar S (2006) Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J Obstet Gynaecol 26:673–678. doi:10.1080/01443610600913932\nIrvine GA, Campbell-Brown MB, Lumsden MA, Heikkilä A, Walker JJ, Cameron IT (1998) Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 105:592–598. doi:10.1111/j.1471-0528.1998.tb10172.x\nLethaby A, Farquhar C, Cooke I (2000) Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev (4):CD000249. doi:10.1002/14651858.CD000249\nLumsden MA, Wedisinghe L (2011) Tranexamic acid therapy for heavy menstrual bleeding. Expert Opin Pharmacother 12:2089–2095. doi:10(1517/14656566),2011,598857\nNaoulou B, Tsai MC (2012) Efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding: a systematic review. Acta Obstet Gynecol Scand. doi:10.1111/j.1600-0412.2012.01361.x\nMoore K, Morin I, Marenco T et al (2012) Pharmacokinetic studies of two novel oral formulations of tranexamic acid therapy for heavy menstrual bleeding. Am J Ther 19:190–198. doi:10.1097/MJT.0b013e318205427a\nLukes A, Moore KA, Muse KN et al (2010) Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 116:865–875. doi:10.1097/AOG.0b013e3181f20177\nFreeman EW, Lukes A, VaDrie D, Mabey RG, Gersten J, Adomako TL (2011) A dose–response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. Am J Obstet Gynecol 205:319.e1–7. doi:10.1016/j.ajog.2011.05.015\nAhrendt HJ, Makalova D, Parke S, Mellinger U, Mansour D (2009) Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception 80:436–444. doi:10.1016/j.contraception.2009.03.018\nJensen JT (2010) Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest. Expert Opin Pharmacother 11:1147–1157. doi:10.1517/14656561003724713\nPalacios S, Wildt L, Parke S, Machlitt A, Römer T, Bitzer J (2010) Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial. Eur J Obstet Gynecol Reprod Biol 149:57–62. doi:10.1016/j.ejogrb.2009.11.001\nWhalen KL, Rose R (2011) Estradiol valerate/dienogest: a novel oral contraceptive. Ann Pharmacother 45:1256–1261. doi:10.1345/aph.1Q216\nKlipping C, Duijkers I, Parke S, Mellinger U, Serrani M, Junge W (2011) Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs R D 11:159–170. doi:10.2165/11591200-000000000-00000\nBorgelt LM, Martell CW (2012) Estradiol valerate/dienogest: a novel combined oral contraceptive. Clin Ther 34:37–55. doi:10.1016/j.clinthera.2011.11.006\nFraser IS, Römer T, Parke S et al (2011) Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing oestradiol valerate and dienogest: a randomised, double-blind phase III trial. Hum Reprod 26:2698–2708. doi:10.1093/humrep/der224\nMicks E, Jensen JT (2011) Estradiol valerate and dienogest: a novel four-phasic oral contraceptive pill effective for pregnancy prevention and treatment of heavy menstrual bleeding. Womens Health (Lond Engl) 7:513–524. doi:10.2217/WHE.11.49\nKiley JW, Shulman LP (2011) Estradiol valerate and dienogest: a new approach to oral contraception. Int J Womens Health 3:281–286. doi:10.2147/IJWH.S22645\nFraser IS, Parke S, Mellinger U, Machlitt A, Serrani M, Jensen J (2011) Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomized, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 16:258–269. doi:10.3109/13625187.2011.591456\nFraser IS, Jensen J, Schaefers M, Mellinger U, Parke S, Serrani M (2012) Normalization of blood loss in women with heavy menstrual bleeding treated with an oral contraceptive containing estradiol valerate/dienogest. Contraception 86:96–101. doi:10.1016/j.contraception.2011.11.011\nKaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, Muysers C, Jensen JT (2010) Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 116:625–632. doi:10.1097/AOG.0b013e3181ec622b\nReid PC, Virtanen-Kari S (2005) Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG 112:1121–1125. doi:10.1111/j.1471-0528.2005.00642.x\nRoumen FJ (2007) The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials. Contraception 75:420–429. doi:10.1016/j.contraception.2007.01.013\nMulders TM, Dieben TO (2001) Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril 75:865–870. doi:10.1016/S0015-0282(01)01689-2\nOddsson K, Leifels-Fischer B, Wiel-Masson D et al (2005) Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. Hum Reprod 20:557–562. doi:10.1093/humrep/deh604\nSabatini R, Cagiano R (2006) Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception 74:220–223. 10.1016/j.contraception.2006.03.022\nJanssen CA, Scholten PC, Heintz AP (1995) A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 85:977–982\nZakherah MS, Sayed GH, El-Nashar SA, Shaaban MM (2011) Pictorial blood loss assessment chart in the evaluation of heavy menstrual bleeding: diagnostic accuracy compared to alkaline hematin. Gynecol Obstet Invest 71:281–284. doi:10.1159/000320336\nLopez LM, Grimes DA, Gallo MF, Schulz KF (2010) Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev (3):CD003552. doi:10.1002/14651858.CD003552.pub3\nBahamondes V, Bahamondes L (2012) “This interesting study shows that that both the contraceptive vaginal ring (CVR) and norethisterone (NET…” Evaluation of: [Abu Hashim H et al. Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception 85:246–252; doi:10.1016/j.contraception.2011.07.012]. Faculty of 1000, 07 Dec 2011. F1000.com/13385972#eval14753078\nBeaumont H, Augood C, Duckitt K, Lethaby A (2007) Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev (3):CD001017. doi:10.1002/14651858.CD001017.pub2\nConflict of interest\nWe declare that we have no conflict of interest.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nAbu Hashim, H. Medical treatment of idiopathic heavy menstrual bleeding. What is new? An evidence based approach. Arch Gynecol Obstet 287, 251–260 (2013). https://doi.org/10.1007/s00404-012-2605-y\nReceived:\nAccepted:\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/s00404-012-2605-y","source_license":"CC0","license_restricted":false}